|Dr. Mondher Mahjoubi||Chairman of Exec. Board & CEO||778.13k||N/A||1958|
|Mr. Yannis Morel||Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board||359.04k||N/A||1973|
|Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA||Exec. VP of Fin. & Corp. Strategy||300.65k||N/A||1978|
|Dr. Herve Brailly||Co-Founder & Chairman of Supervisory Board||N/A||N/A||1961|
|Dr. FranÃ§ois RomagnÃ©||Founder||N/A||N/A||1964|
|Mr. Eric Vivier D.V.M., M.B.A., Ph.D.||Founder, Sr. VP & Chief Scientific Officer||N/A||N/A||1964|
|Dr. Marc Bonneville||Founder||N/A||N/A||1960|
|Mr. Jean Jacques FourniÃ© Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Alessandro Moretta M.D., Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Frederic Lombard M.B.A.||Sr. VP & CFO||N/A||N/A||N/A|
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sÃ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Innate Pharma S.A.’s ISS governance QualityScore as of 1 July 2021 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 3; Compensation: 10.